Psoriasis: News

• Experimental Topical Drug Shows Promise for AD, Psoriasis In the phase 2 study, researchers at 34 sites in four countries randomized 104 patients with mild to moderate AD or psoriasis to receive the topical PDE4 inhibitor or a vehicle once daily for 6 weeks.
  MDedge News, January 04, 2024
  2
• Keeping Injectable Products in Cosmetic Dermatology Safe The rapid increase in intradermal injections of hyaluronic acid and Botox has been accompanied by an increase in side effects.
  Medscape Medical News, December 26, 2023
• Paradoxical Eczema Risk Low With Biologic Psoriasis Tx Ali Al-Janabi, MA, and associates found that 273 (1%) of approximately 25,000 drug exposures in 13,699 biologic-treated patients with psoriasis were associated with paradoxical eczema.
  MDedge News, December 22, 2023
• Reducing CVD Morbidity and Mortality in Psoriasis and PsA Only a minority of patients with psoriatic disease know about their increased risks.
  MDedge News, December 20, 2023
  1
• Alert Roflumilast Foam Gets Nod for Seborrheic Dermatitis Patients in the roflumilast group showed significant improvements in all secondary endpoints, including itching, scaling, and erythema.
  MDedge News, December 18, 2023
• Bimekizumab Promising for Palmoplantar Pustular Psoriasis PPP is a type of pustular psoriasis that remains a treatment challenge, and available treatments for palmoplantar plaque psoriasis with pustules also "remain unsatisfactory."
  MDedge News, December 12, 2023
  1
• Tape Strips Detect Hidradenitis Suppurativa Biomarkers "Tape strips can provide important clues to when and which drugs to use in HS in patients with both early and late disease, which can change clinical practice."
  MDedge News, December 08, 2023
• Patients With hEDS Report Skin Laxity, Scarring Follicular occlusion, mast cell disease, and eczema were common presentations among patients with hypermobile Ehlers-Danlos syndrome.
  MDedge News, December 07, 2023
  2
• Analysis Supports Link Between Psoriasis and OSA Several hypotheses may explain the connection, such as the presence of inflammatory mediators and nocturnal cytokine secretion, according to the authors.
  Medscape Medical News, December 04, 2023
• MSWS 2023 Misdiagnoses Among Challenges in Managing Cutaneous Lymphoma Although predictive tools to identify those at risk of disease progression are in their infancy, the development of such tools is crucial for improving patient outcomes.
  Medscape Medical News, December 02, 2023
• Nail Psoriasis in Black Patients Often Overlooked Underrepresentation of Black patients with psoriasis in trials and textbooks might partially explain why clinicians are slow to recognize nail involvement, even after psoriasis has been diagnosed.
  MDedge News, November 28, 2023
• HS: Positive Results Reported With Anti-IL17A/F Therapies One of the trials evaluated a nanobody inhibitor, sonelokimab, a molecule with a substantially smaller size than traditional monoclonal antibodies.
  MDedge News, November 28, 2023
• Parent Concerns a Factor When Treating Patients With AD For a parent whose child has an inflammatory skin disease, pigmentation changes, rather than inflammation, might be the reason that he or she brought the child to the clinician.
  MDedge News, November 23, 2023
  1
• ACR 2023 IV Secukinumab Trials Hit Primary Endpoints in PsA, AxSpA Two phase 3 trials of the recently approved IV formulation of secukinumab showed its efficacy vs placebo in treating psoriatic arthritis and axial spondyloarthritis.
  MDedge News, November 20, 2023
• ACR 2023 First Referral Guide Issued for Axial Spondyloarthritis The draft recommendations are a 'good first step,' but more awareness around axial spondyloarthritis in the non-rheumatology community is also needed to improve diagnosis, one expert said.
  Medscape Medical News, November 15, 2023
  3
• ACR 2023 Apremilast Beats Placebo in Early PsA Affecting Few Joints Oligoarticular PsA can significantly affect quality of life even though few joints are affected, and there's a lack of relevant clinical data to guide treatment.
  MDedge News, November 15, 2023
• AAD Updates Guidelines for Managing AD The guidelines cover approved and off-label uses of systemic therapies and phototherapy, including new treatments that have become available since the last guidelines were published in 2014.
  MDedge News, November 13, 2023
• ACR 2023 TNF Blockers Not Associated With Poorer Pregnancy Outcomes Patients with rheumatic disease who continued TNF blockers during their pregnancy did not have an increased risk of worse fetal and maternal outcomes and had a lower risk of severe infection.
  Medscape Medical News, November 13, 2023
• Palmoplantar Pustulosis: Treatment Challenges When it comes to pustular disease localized to the hands and feet, treatment options have only modest efficacy, according to speakers at the annual National Psoriasis Foundation research symposium.
  MDedge News, November 13, 2023
• Teasing Apart Multiple Biologic Failure in Psoriasis, PsA 'Tough-to-treat psoriasis remains a challenge despite newer therapies ... Why do we still have this sub-population of patients who seem to be refractory?'
  MDedge News, November 08, 2023
• Ready to Start Engaging on Social Media? In the opinion of Swati Kannan, MD, deciding whether or not to establish a presence on social media starts with a gut-check about your intentions.
  MDedge News, November 03, 2023
• Alert FDA Approves First Ustekinumab Biosimilar The drug has also been granted an interchangeability designation and has been approved for six indications.
  Medscape Medical News, November 01, 2023
• Positive Trial of Methotrexate in Hand OA Has Modest Results A randomized controlled trial of methotrexate in inflammatory hand OA demonstrated clinical benefit, suggesting a potential role for immunosuppression in a subset of patients with an inflammatory OA phenotype.
  Medscape Medical News, October 30, 2023
  2
• BMS Says It Needs Another Year to Hit Target for New Drugs Bristol Myers Squibb on Thursday pushed back by a year the time frame for its new-product portfolio to hit $10 billion in revenue as the sales ramp-up of medicines such as psoriasis treatment Sotyktu and multiple sclerosis drug Zeposia takes longer than initially projected.
  Reuters Health Information, October 26, 2023
• Phenotype-Targeted Treatment Sought for Psoriatic Disease Researchers described ongoing work to "understand the discrete and overlapping endotypes that underlie the phenotypes" of psoriatic disease and to develop a diagnostic test for psoriatic arthritis.
  Medscape Medical News, October 25, 2023
  1
• Shared Decision-Making Low in Patients With Psoriasis The study findings underscore the importance of enhancing clinician-patient communication, the authors say.
  Medscape Medical News, October 25, 2023
• Strategy Shows Promise for Psoriasis Remission in Early Study The study is investigating whether high-dose IL-23 inhibition can target resident memory T cells and thereby induce long-term remission.
  MDedge News, October 24, 2023
• Alert FDA Approves Bimekizumab for Plaque Psoriasis in Adults Bimekizumab is the first IL-17A and IL-17F inhibitor approved by the FDA for adults with psoriasis.
  Medscape Medical News, October 18, 2023
• EADV 2023 Patients With Psoriasis Lose Weight With Roflumilast: Study Oral roflumilast not only appears to improve skin symptoms, but it could also help with weight loss, results of the phase 2 PSORRO study suggest.
  Medscape Medical News, October 13, 2023
  1